Lilly Invests $3.5 Billion in Pennsylvania Drug Manufacturing Plant, Creating 850 Jobs
Eli Lilly breaks ground on a $3.5B injectable medicine plant in Fogelsville, PA, creating 850 jobs and producing retatrutide, a new obesity treatment, by 2
Research Desk
Eli Lilly and Company has started construction on a USD 3.5 billion injectable medicine plant in Fogelsville, in Pennsylvania's Lehigh Valley.
The facility will manufacture retatrutide, a first-in-class investigational GIP, GLP-1, and glucagon triple hormone receptor agonist being developed to treat obesity, along with other injectable medicines. Lilly expects the site to be operational by 2031.
A Workforce of 850 and Roughly 2,000 Construction Roles
The Fogelsville project is projected to generate 850 high-wage positions, spanning engineers, scientists, operations staff, and lab technicians, while roughly 2,000 construction jobs will be created as the site is built and brought online. Lilly is hiring in the Lehigh Valley now.
Advanced technology will be central to operations. The plant will combine its skilled workforce with machine learning, AI, digitally integrated systems, and advanced data analytics, all designed to drive right-first-time execution, with digital automation embedded throughout to streamline production.
Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations, described the quality discipline behind the company's production: "Before a dose of medicine leaves one of our sites, each production run goes through more than 5,000 documented steps, and each unit is imaged and inspected more than 70 times to check for defects."
He said Lehigh Valley will build on that discipline with next-generation automation and digital systems, so medicines made in Pennsylvania can be counted on for years to come.
Why Lilly Is Betting on the Lehigh Valley
Lilly Chair and CEO David A. Ricks framed the investment around the accelerating science of obesity care.
"Obesity is one of the biggest health challenges of our time, and the science to treat it is moving quickly," he said.
He added that retatrutide is one of several next-generation medicines under development that could help millions more people living with obesity, type 2 diabetes, or both, and that the USD 3.5 billion investment will allow the company to make those medicines in Pennsylvania for people at home and around the world.
The facility is one of 10 new U.S. manufacturing sites Lilly has announced since 2020 and one of four among those dedicated to injectable medicines and devices. It forms part of the company's USD 50 billion push to expand medicine production across the United States, adding capacity for the next generation of obesity treatments.
Officials Praise the Investment
Pennsylvania Governor Josh Shapiro described the groundbreaking as "another historic milestone in Pennsylvania's thriving life sciences sector," crediting the state's workforce, research institutions, infrastructure, and resources for attracting the investment.
U.S. Senator Dave McCormick called it "another major win for Pennsylvania, bringing 850 high-paying jobs, strengthening American manufacturing, and cementing the Commonwealth's position" as a leader in the industry.
Jeff Fleischaker, Chairman of the Upper Macungie Township Board of Supervisors, said the township's Board, staff, and residents are pleased to welcome Lilly to the community.
USD 1 Million for the Local Community Fund
Alongside the plant itself, Lilly has committed up to USD 1 million over five years to the Upper Macungie Township Community Fund.
The money is earmarked for an anticipated new initiative at the Upper Macungie Community Center intended to develop a quality-of-life program for Lehigh Valley families, with a focus on nutrition and healthy living, fresh food access, health resources, and community programming.
LEED Gold Targeted as Lilly Grows Its U.S. Footprint
The Fogelsville facility will be built and operated to standards for safety, quality, and environmental stewardship and is targeting Leadership in Energy and Environmental Design (LEED) Gold certification.
Lilly says the target reflects its focus on sustainable performance as it expands advanced manufacturing in the United States. The Lehigh Valley plant fits within a broader network Lilly has been assembling.
Of the 10 U.S. sites announced since 2020, five will produce active pharmaceutical ingredients: Richmond, Virginia; Huntsville, Alabama; Houston, Texas; and two sites in Lebanon, Indiana: Lebanon API and Lilly Medicine Foundry, the latter also focused on new production methods and medicines for clinical trials.
Four sites are dedicated to injectable medicines and device manufacturing: Research Triangle Park and Concord, North Carolina; Kenosha, Wisconsin; and the new Lehigh Valley site in Pennsylvania. A tenth facility, Lebanon Advanced Therapies in Lebanon, Indiana, will make genetic medicines.
Tracked in the database
New Manufacturing Facility Announcement · North America
New Manufacturing Facility Announcement
North America
Chemical
13 November 2026
3 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.